Form 4: Lexicon Pharmaceuticals Executive Alan J. Main Reports Stock Transactions

Alan J. Main, EVP of Innovation & Chemical Sciences at Lexicon Pharmaceuticals, reports the vesting and subsequent sale of restricted stock units to cover tax obligations.

Summary

• On February 28, 2025, Alan J. Main, EVP of Innovation & Chemical Sciences at Lexicon Pharmaceuticals, executed transactions involving restricted stock units.
• These transactions involved the vesting of 25,667, 32,904, and 68,243 restricted stock units, which convert into an equal number of common stock shares.
• Following the vesting, shares were withheld by the company to satisfy tax obligations, resulting in the disposition of 43,434 shares at a price of $0.67.
• After these transactions, Main directly owns 339,104 shares of Lexicon Pharmaceuticals common stock, as well as 0, 32,903, and 136,487 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve the vesting and sale of shares by an executive.
• The company's withholding of shares for tax obligations ensures compliance with tax regulations.

Key Dates